MacroHint

MACROHINT

Menu
Contact Us

MACROHINT

MacroHint

Datadog and Palo Alto Are Going Shopping—And They’re Not Bargain Hunting

Leave a Comment / Uncategorized /

This article is proudly sponsored by Texas Student Media! Datadog and Palo Alto Are Going Shopping—And They’re Not Bargain Hunting When $1 billion is your warm-up act, you know tech M&A is back in heat. In two separate but equally spicy headlines, two cybersecurity powerhouses are reportedly preparing to go on major spending sprees: Datadog (NASDAQ: […]

Datadog and Palo Alto Are Going Shopping—And They’re Not Bargain Hunting Read More »

Buffett Says “Nope” to Railroad Merger Rumors—But the Tracks Are Still Getting Hot

Leave a Comment / Uncategorized /

This article is proudly sponsored by Lake Region State College! Buffett Says “Nope” to Railroad Merger Rumors—But the Tracks Are Still Getting Hot Warren Buffett isn’t buying a railroad this week. But someone probably is. In classic Buffett fashion, the Oracle of Omaha stepped in this morning to pour cold water on the latest round of

Buffett Says “Nope” to Railroad Merger Rumors—But the Tracks Are Still Getting Hot Read More »

Labcorp Just Bought CHS’s Lab Biz for $195 Million—And It Might Be the Best Divorce of the Year

Leave a Comment / Uncategorized /

This article is proudly sponsored by Lake Region State College! Labcorp Just Bought CHS’s Lab Biz for $195 Million—And It Might Be the Best Divorce of the Year Because nothing says “we need space” like handing over 13 states’ worth of lab operations for cold, hard cash. On July 22, 2025, Community Health Systems (NYSE: CYH)

Labcorp Just Bought CHS’s Lab Biz for $195 Million—And It Might Be the Best Divorce of the Year Read More »

Jamie Dimon Once Called Bitcoin a Fraud. Now JPMorgan Might Lend Against It

Leave a Comment / Uncategorized /

This article is proudly sponsored by Texas Student Media! Jamie Dimon Once Called Bitcoin a Fraud. Now JPMorgan Might Lend Against It From “worthless” to “we’ll take it as collateral” in just eight short years. In a plot twist worthy of its own NFT collection, JPMorgan (NYSE: JPM) is reportedly preparing to offer crypto-backed loans—letting clients

Jamie Dimon Once Called Bitcoin a Fraud. Now JPMorgan Might Lend Against It Read More »

Inside Heard Capital’s High-Conviction Portfolio: The 10 Stocks William Heard Is Betting Big On

Leave a Comment / Uncategorized /

This article is sponsored by College Readiness Consulting! Inside Heard Capital’s High-Conviction Portfolio: The 10 Stocks William Heard Is Betting Big On Some hedge funds chase hype. Others compound capital based on fundamentals and focus on the bottom-up. Heard Capital is firmly in the second camp. William Heard’s most recently filed Q1 2025 13F reveals

Inside Heard Capital’s High-Conviction Portfolio: The 10 Stocks William Heard Is Betting Big On Read More »

Why Dover (DOV) Is a Top Industrial Stock to Buy for a Gradual Fed Rate Cut Cycle

Leave a Comment / Uncategorized /

This article is proudly sponsored by Sew Torn, a film by Diamantis Zavitsanos! Why Dover (DOV) Is a Top Industrial Stock to Buy for a Gradual Fed Rate Cut Cycle As the Federal Reserve slowly begins preparing to shift into a rate-cutting cycle—likely gradual, data-dependent, and carefully telegraphed, so could be delayed given that all of

Why Dover (DOV) Is a Top Industrial Stock to Buy for a Gradual Fed Rate Cut Cycle Read More »

Why Maverick Capital Just Bought Merit Medical (MMSI): A Hidden Winner for 2026 Rate Cuts

Leave a Comment / Uncategorized /

This article is proudly sponsored by Lake Region State College! Why Maverick Capital Just Bought Merit Medical (MMSI): A Hidden Winner for 2026 Rate Cuts When Lee Ainslie’s Maverick Capital—a $7B+ long/short hedge fund known for sharp fundamental bets— initiated a brand-new position in Merit Medical Systems (NASDAQ: MMSI) during Q1 2025, it personally raised more

Why Maverick Capital Just Bought Merit Medical (MMSI): A Hidden Winner for 2026 Rate Cuts Read More »

Why UnitedHealth Is Still More Likely Than Not to Close the Amedisys Deal

Leave a Comment / Uncategorized /

This article is sponsored by College Readiness Consulting! Why UnitedHealth Is Still More Likely Than Not to Close the Amedisys Deal Amedisys (NASDAQ: AMED) investors are panicking again. A proposed 6.4% Medicare cut for 2026. A DOJ lawsuit. And headlines hinting that UnitedHealth (NYSE: UNH) might walk. But here’s my view: This deal is still

Why UnitedHealth Is Still More Likely Than Not to Close the Amedisys Deal Read More »

Eastman Chemical (EMN) Is a Sneaky-Good Rate Cut Play — Here’s Why

Leave a Comment / Uncategorized /

This article is proudly sponsored by Lake Region State College! Eastman Chemical (EMN) Is a Sneaky-Good Rate Cut Play — Here’s Why As Wall Street plays musical chairs with every whisper from Jerome Powell, smart investors are scanning for more than just the usual suspects in a rate-cut environment. Everyone’s talking about banks, REITs, and tech.

Eastman Chemical (EMN) Is a Sneaky-Good Rate Cut Play — Here’s Why Read More »